AASLD 2022 | Novel and accurate measurement of differential protease activity in diagnosed HCC patients compared to non-HCC cirrhotic patients November 4, 2022 in Events & Resources, Publications /by david
Glympse to Present Data Demonstrating Sensitive Detection of Hepatocellular Carcinoma at AASLD The Liver Meeting 2022 October 25, 2022 in Press Releases /by david
PharmaVoice | Woman of the Week: Glympse Bio’s Dr. Tram Tran (Podcast) August 24, 2022 in In the News /by david
EASL ILC 2022 | Novel and accurate measurement of differential protease activity in diagnosed HCC patients compared to non-HCC cirrhotic patients June 22, 2022 in Publications /by david
EASL ILC 2022 | Measurement of Protease Activity Using Novel Plasma Biosensors Can Accurately Detect HCC from Healthy Controls June 22, 2022 in Publications /by david
Glympse to Present Two Posters Demonstrating Novel Protease Biosensor Diagnostic Platform Detection of Hepatocellular Carcinoma at EASL ILC 2022 June 8, 2022 in Press Releases /by david
Glympse Appoints Jonathan Wilde, Ph.D., as Chief Scientific Officer to Advance Biosensor Assay Platform May 17, 2022 in Press Releases /by david
Drug Discovery News | Goodbye biopsies, non-invasive diagnostics for fatty liver disease are here May 13, 2022 in In the News /by david
